← Back to Clinical Trials
Recruiting NCT07643337

NCT07643337 Impact of VNS With Rehab on Gait Post-Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07643337
Status Recruiting
Phase
Sponsor State University of New York at Buffalo
Condition Upper Limb Deficit
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2026-06
Primary Completion 2027-12-15

Eligibility & Interventions

Sex All sexes
Min Age 22 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Vagus Nerve Stimulation Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2026-06 with a primary completion date of 2027-12-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective, double-blinded, randomized controlled study to evaluate the impact of Vagus Nerve Stimulation (VNS) therapy on lower limb function.

Eligibility Criteria

Inclusion Criteria: * Approved for Vagus Nerve Stimulation (VNS) and rehabilitation therapy * ≥22 years and ≤ 80 years * Only patients who elect to undergo VNS therapy for stroke-related upper limb deficits * Residual active movement in the affected limb's thumb and other 2 fingers * Stroke-related deficits in the lower limbs and gait with a Functional Ambulation Category (FAC) ≥3 * Able to follow simple instructions and independently walk short distances with or without external support or leg orthoses, but without manual contact with another person Exclusion Criteria: * Intact lower limb functions (Fugl-Meyer score=34) * Not a candidate for VNS therapy according to FDA guidelines * Pregnant patients

Contact & Investigator

Central Contact

Ellen M Carl, PhD, CCRP

✉ ecarl@ubns.com

📞 716-218-1000

Principal Investigator

Assaf Berger, MD

PRINCIPAL INVESTIGATOR

University at Buffalo

Frequently Asked Questions

Who can join the NCT07643337 clinical trial?

This trial is open to participants of all sexes, aged 22 Years or older, up to 80 Years, studying Upper Limb Deficit. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07643337 currently recruiting?

Yes, NCT07643337 is actively recruiting participants. Contact the research team at ecarl@ubns.com for enrollment information.

Where is the NCT07643337 trial being conducted?

This trial is being conducted at Buffalo, United States.

Who is sponsoring the NCT07643337 clinical trial?

NCT07643337 is sponsored by State University of New York at Buffalo. The principal investigator is Assaf Berger, MD at University at Buffalo. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology